Last Updated: 31/01/2025
Post-discharge Malaria Chemoprevention (PMC) Study (PMC)
Objectives
This study evaluates the efficacy and safety of 3 months of malaria chemoprevention post-discharge using dihydroartemisinin-piperaquine (DHA-P) in children under 5 years of age admitted with severe anemia. One half will receive monthly DHA-P and the other half placebo.
The primary objective is to determine if 3 months of post-discharge malaria chemoprevention with monthly 3-day treatment courses of DP is superior to the single 3-day treatment course with artemether-lumefantrine provided as part of standard in-hospital care in reducing all-cause readmissions and deaths by 6 months in the post-discharge management of children less than 5 years of age admitted with severe anaemia.
University of Bergen, Norway
Liverpool School of Tropical Medicine (LSTM), United Kingdom
Makerere University, Uganda
Kenya Medical Research Institute (KEMRI), Kenya
ClinicalTrials.gov Identifier: NCT02671175
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 2212 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
Kwambai, N Engl J Med, 2020; Malaria Chemoprevention in the Postdischarge Management of Severe AnemiaKwambai, Trials, 2018; Malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya
May 2016 — Mar 2019
Related Resources
